Evidence map›Paper›PMID 39001544›Full record

ArticleCancers2024

Germline Sequencing of DNA Damage Repair Genes in Two Hereditary Prostate Cancer Cohorts Reveals New Disease Risk-Associated Gene Variants.

Georgea R Foley, James R Marthick, Sionne E Lucas, Kelsie Raspin, Annette Banks, Janet L Stanford, Elaine A Ostrander, Liesel M FitzGerald, Joanne L Dickinson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Georgea R FoleyMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia.ORCID 0000-0002-2548-0093
James R MarthickMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia.
Sionne E LucasMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia.
Kelsie RaspinMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia.ORCID 0000-0001-8463-6820
Annette BanksMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia.ORCID 0000-0003-3913-7103
Janet L StanfordFred Hutchinson Cancer Center, 1100 Fairview Ave. N., M4-B874, Seattle, WA 98109, USA.
Elaine A OstranderCancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0001-6075-9738
Liesel M FitzGeraldMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia.ORCID 0000-0002-6882-2698
Joanne L DickinsonMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS 7000, Australia.

Funding

Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Prostate Cancer Susceptibility: The ICPCG StudyU01CA089600 · NCI · MAYO CLINIC ROCHESTER · PI THIBODEAU, STEPHEN NORMAN · 2002 to 2016
$27.3M
GENETIC EPIDEMIOLOGY OF PROSTATE CANCERR01CA080122 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STANFORD, JANET L · 1999 to 2008
$3.8M
Cancer Australia NACancer Council Tasmania NAIMPACT Perpetual Trustees IPAP20210253Institute for Prostate Cancer Research of the University of Washington Medicine and Fred Hutchinson Cancer Center NAMax Bruce Trust NANCI NIH HHS P30 CA015704NCI NIH HHS R01 CA080122NCI NIH HHS U01 CA089600Robert Malcom Familial Prostate Cancer Bequest NARoyal Hobart Hospital Research Foundation NATasmanian Community Fund NAThe Estate of Dr RA Parker NAThe Mazda Foundation NA
6 · The paper itself

Abstract

Rare, inherited variants in DNA damage repair (DDR) genes have a recognised role in prostate cancer (PrCa) susceptibility. In addition, these genes are therapeutically targetable. While rare variants are informing clinical management in other common cancers, defining the rare disease-associated variants in PrCa has been challenging. Here, whole-genome and -exome sequencing data from two independent, high-risk Australian and North American familial PrCa datasets were interrogated for novel DDR risk variants. Rare DDR gene variants (predicted to be damaging and present in two or more family members) were identified and subsequently genotyped in 1963 individuals (700 familial and 459 sporadic PrCa cases, 482 unaffected relatives, and 322 screened controls), and association analyses accounting for relatedness (M

Indexed as

DNA repairgenetic susceptibilitygermline variantsprostate cancerrare high-risk genes

Identifiers

PMID39001544
PMCPMC11240467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.